This Highlights of ASH program is based on a selection of abstracts presented at the 51^st ASH Annual Meeting that are of greatest interest to practitioners. The 2010 program schedule focuses on pathophysiology, diagnosis and management of common malignant and benign hematologic disorders including acute and chronic leukemias, lymphomas, myeloma, thrombotic disorders, myelodisplastic syndromes, and myeloproliferative disorders.

At the completion of the program, attendees will be able to:

• Characterize new insights into the biology of acute leukemia; summarize current assessments of potential new agents for treatment of acute myeloid leukemia.
• Examine new knowledge about the etiology of MDS; update the participants about new agents to treat MDS.
• Summarize updates on management of CML, including monitoring, and relapsed/refractory disease; summarize new information on the diagnosis, prognosis, and therapy of Ph-negative myeloproliferative neoplasms.
• Describe the role of new specific treatments for CLL including immunomodulatory agents, purine analogues, monoclonal antibodies, immunotherapeutics, and other newly tested agents.
• Explore newer insights into molecular biology of B-cell neoplasms; examine new data on effectiveness and toxicity of targeted agents for B-cell lymphomas.
• Understand updated data on effectiveness of standard and experimental treatments for Hodgkin lymphoma; describe the best integration of the twin goals of effective treatment and minimization of toxicity for Hodgkin lymphoma.
• Describe new insights into the basic abnormalities of hemostasis that lead to abnormal clotting.
• Review newly available information about the role, effectiveness and complications of newer treatments for ITP.
• Summarize updated information about newer anti-thrombotic agents; describe new insights into management f complex situations in which abnormal thrombosis occurs.
• Summarize updated information about basic mechanisms of iron absorption and utilization; understand new information about classification of anemic states.
• Summarize the latest results from major studies of new approaches to myeloma treatment; examine the evidence justifying new approaches to management of newly diagnosed and relapsed myeloma.
• Summarize updated information on new aspects of management of patients during high dose chemotherapy and hematopoietic stem cell transplantation (HSCT); summarize information on new insights into the appropriate integration of HSCT into the management of lymphoid and myeloid malignancies.

back to top